The next tech war? Why biotech may become a new US-China battleground

AI Summary

The US-China geopolitical rivalry is expanding into biotechnology, raising the possibility of new tensions in the sector as American pharma firms increasingly engage with China’s booming biotech industry. Significant investment and development in biotech are driving this emerging battleground.

The wide-ranging geopolitical rivalry between Beijing and Washington could soon expand into biotechnology, raising the prospect of fresh tensions even as American pharmaceutical firms have turned to China’s fast-growing industry for new drug candidates. Biotech in the world’s second-largest economy has long been viewed as a predominantly low-cost manufacturing base with opportunities arising from its vast domestic market. But years of sustained investment, cost advantages and faster development...